Skip to main content
. 2024 Feb 6;47(3):310–324. doi: 10.1007/s00270-023-03657-x

Table 2.

Treatments before and after TARE

Category Subcategory ICC (n = 174)
Intention of treatmenta n 174 (100)
Palliative 128 (73.6)
Downsizing 33 (19)
Bridge to ablation 8 (4.6)
Bridge to liver surgery 3 (1.7)
Bridge to liver transplant 2 (1.1)
Position of TARE in the continuum of care n 158 (90.8)
First-line TARE 62 (35.6)
First-line TARE plus concomitant systemic therapyc 20 (11.5)
Second line TARE 54 (31)
 > 2nd line TARE 22 (12.6)
Hepatic procedures prior to TARE n 174 (100)
Yes 49 (28.2)
No 125 (71.8)
Type of hepatic proceduresb n 49 (100)
Surgical (any) 37 (75.5)
Ablation (any) 8 (16.3)
TACE (any) 2 (4.1)
Other embolotherapies (any) 1 (2)
Abdominal radiotherapy (any) 9 (18.4)
Systemic therapy after TARE n 174 (100)
Yes 84 (48.3)
Noc 90 (51.7)
Number of systemic therapy lines after TARE n 83 (98.8)
1 Line 37 (44)
2–5 Lines 31 (36.9)
6 or more lines 15 (17.6)
Hepatic procedures after TARE Yes 29 (16.7)
No 145 (83.3)
Type of hepatic procedures after TAREd n 29 (100)
Surgical (any) 12 (41.4)
Ablation (any) 5 (17.2)
TACE (any) 1 (3.4)
Other embolotherapies (any) 4 (13.8)
Abdominal radiotherapy (any) 12 (41.4)
Not reported 3 (10.3)

N (%)

aIntention of TARE is for first treatment

bPatients can have multiple prior and post-TARE hepatic procedures

cConcomitant therapy is defined as any systemic therapy that starts within 56 days before or after TARE

dNo systemic therapy after TARE includes patients that were lost to follow-up or deceased before the first follow-up could be included (12 [10] for CIRT and 2 [3.7] for CIRT-FR)

ICC intrahepatic cholangiocarcinoma, TACE transarterial chemoembolization, TARE transarterial radioembolization

Categories where percentages (%) do not add up to 100 are due to missing information